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Abstract
Purpose: Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis are at risk for multiple nerve sheath tumors
and premature mortality. Traditional magnetic resonance imaging (MRI) has limited ability to assess disease burden
accurately. The aim of this study was to establish an international cohort of patients with quantified whole-body internal
tumor burden and to correlate tumor burden with clinical features of disease.
Methods: We determined the number, volume, and distribution of internal nerve sheath tumors in patients using whole-
body MRI (WBMRI) and three-dimensional computerized volumetry. We quantified the distribution of tumor volume across
body regions and used unsupervised cluster analysis to group patients based on tumor distribution. We correlated the
presence and volume of internal tumors with disease-related and demographic factors.
Results: WBMRI identified 1286 tumors in 145/247 patients (59%). Schwannomatosis patients had the highest prevalence of
tumors (P = 0.03), but NF1 patients had the highest median tumor volume (P = 0.02). Tumor volume was unevenly
distributed across body regions with overrepresentation of the head/neck and pelvis. Risk factors for internal nerve sheath
tumors included decreasing numbers of cafe´-au-lait macules in NF1 patients (P = 0.003) and history of skeletal abnormalities
in NF2 patients (P = 0.09). Risk factors for higher tumor volume included female gender (P = 0.05) and increasing
subcutaneous neurofibromas (P = 0.03) in NF1 patients, absence of cutaneous schwannomas in NF2 patients (P = 0.06), and
increasing age in schwannomatosis patients (p = 0.10).
Conclusion: WBMRI provides a comprehensive phenotype of neurofibromatosis patients, identifies distinct anatomic
subgroups, and provides the basis for investigating molecular biomarkers that correlate with unique disease manifestations.
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Introduction
The neurofibromatoses, including NF1, NF2, and schwannoma-
tosis, are hereditary tumor predisposition syndromes caused by
germline mutations in the NF1, NF2, and SMARCB1 tumor-
suppressor genes, respectively.[1–4] Biallelic inactivation of these
tumor-suppressor genes in susceptible cells leads to dysregulation of
key cellular machinery, including activation of the Ras pathway
(NF1), loss of contact-dependent inhibition of the EGFR pathway
(NF2), and perturbation of the SWI-SNF chromatin remodeling
complex (schwannomatosis).
These related syndromes have overlapping clinical features and
for years, clinicians struggled to differentiate the types of
neurofibromatosis. Clinical criteria were established for NF1 and
NF2 in 1987 and for schwannomatosis in 2005.[5,6] These patients
share a predisposition to developing benign nerve sheath tumors,
including neurofibromas and schwannomas, that are derived from
neoplastic Schwann cells. Despite the benign histology of neurofi-
bromas and schwannomas, neurofibromatosis patients have in-
creased mortality due to malignant peripheral nerve sheath tumor
(MPNST), glioma, cardiovascular disease, and organ compression
by neurofibromas.[7,8] For NF1 patients, themedian age at death is
59 years, compared with 74 years for the general population.[9] For
NF2 patients, actuarial survival after diagnosis is 85% at 5 years,
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35711
67% at 10 years, and 38% at 20 years.[10] Mortality figures for
schwannomatosis have not been reported.
The spectrum of tumor involvement of these disorders is highly
variable. In practice, clinicians carefully select the body region to
image based on the presence of symptoms and knowledge of
disease phenotype (e.g., cranial MRI for vestibular schwannomas
in NF2 patients). Imaging of the entire body using traditional
regional scans is not possible due to the cost (in time and money) of
MRI. For this reason, data regarding the prevalence of whole-
body disease patterns from large, multicenter cohorts are lacking.
Whole-body MRI (WBMRI) can evaluate the entire body in a
relatively short time without the use of ionizing radiation. We
performed an international multicenter study of WBMRI to assess
tumor burden of internal nerve sheath tumors in NF1, NF2, and
schwannomatosis. Our goal was to identify phenotypic similarities
among these related neurogenetic disorders, to identify patterns of
tumor involvement, and to relate tumor burden to demographic
factors and cutaneous disease manifestations.
Methods
Whole-body MRI
We performed WBMRI in patients with NF1, NF2, or
schwannomatosis.[5,11,12] Inclusion criteria for the study includ-
ed age $18 years of age; diagnosis of NF1, NF2, or schwanno-
matosis by clinical criteria;[5,11,12] and ability to provide written
informed consent. Exclusion criteria included inability to undergo
MRI because of a medical or psychological condition; presence of
a metallic implant; need for general anesthesia; pregnancy; or
breast-feeding. Patients were drawn from a convenience sample of
patients seen at the Neurofibromatosis clinics at Massachusetts
General Hospital and University of Hamburg, Eppendorf,
Germany.
Determination of tumor burden
WBMRI was performed once per individual as previously
described.[13] MRI scans were first reviewed by a board-certified
radiologist who identified the location and appearance (circum-
scribed vs. plexiform) of each tumor based on its MRI appearance.
Tumors that were locally circumscribed on MRI were classified as
circumscribed and those that were invasive or involved multiple
nerves were classified as plexiform (Figure 1). Pathological diagnosis
was not required. Second, each tumor was segmented using
computerized volumetry method developed for WBMRI.[13]
Third, the study radiologist reviewed the computerized tumor
contours. Finally, whole-body tumor burden was determined by
recording the number, location, appearance (circumscribed vs.
plexiform), and volume of individual tumors for each patient.
Statistical analysis
Whole-body tumor analysis. We calculated descriptive
statistics for clinical and demographic factors for each disease
group and compared these factors using Kruskal-Wallis test for
continuous variables and Chi-square test for categorical variables.
We compared whole-body tumor burden among disease groups
using Kruskal-Wallis test.
We used whole-body imaging data to identify risk factors
associated with internal nerve sheath tumors. We first used logistic
regression to analyze the relationship between the presence/
absence of internal tumors and clinical/demographic factors. We
then used multivariable linear regression to analyze the relation-
ship between tumor volume and clinical/demographic factors in
patients with at least one internal tumor. In our analysis, we
included clinical and demographic factors previously associated
with paraspinal neurofibromas in NF1 and with disease severity in
NF2[14–16]; we included additional clinical factors to explore
their relationship with tumor burden. For multivariable analyses,
we included age, gender, inheritance pattern (sporadic vs. familial),
number of cafe´-au-lait macules (0 vs. 1–5 vs. 6–15, vs. .15), and
history of skeletal abnormalities as covariates in all patients. In
NF1 patients only, we included the presence of gliomas, number of
cutaneous neurofibromas (0, 1–9, 10–100, 101–500, .500)[17]
and number of subcutaneous neurofibromas (0, 1–9, 10–100, 101–
500, .500) as covariates. In NF2 patients only, we included the
presence of meningiomas and cutaneous schwannomas as
covariates. Tumor volumes were natural log-transformed prior
to multivariable regression analyses.
Distribution analysis. We calculated the absolute and
relative tumor volume in six anatomic regions (head/neck, chest,
abdomen, pelvis, arms, and legs) in patients with internal tumors.
We then quantified the distribution of tumor volume across body
regions for each patient (i.e., regionality of tumor burden) using
the Gini coefficient.[18] A low Gini coefficient indicates a more
even distribution across body parts, with a value of 0
corresponding to uniform distribution of tumor volume across
body regions; higher Gini coefficients indicate a more unequal
distribution with a value of 1 corresponding to concentration of
tumor volume to a single body region.
Figure 1. Appearance of internal nerve sheath tumors on
Whole-Body MRI. Tumor type was defined according to the
radiologic appearance without need for pathological diagnosis. Tumors
that were locally circumscribed on MRI scan were classified as
circumscribed tumors and those that were invasive or involved multiple
nerves were classified as plexiform tumors.
doi:10.1371/journal.pone.0035711.g001
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We then identified specific body regions preferentially affected
by tumors. We adjusted our analysis to account for known
differences in the size of each body part.[19] In this analysis, the
null hypothesis was that the percentage of whole-body tumor
volume in each body part would be equivalent to the percentage of
whole-body volume of each body part. To determine the average
volume of each body part, we measured the volume of body parts
in 5 male and 5 female patients selected at random. We then used
a bootstrap method to test for significance of the Manhattan
distance between the predicted distribution and the observed
average distribution.
We next used unsupervised cluster analysis to sort patients into
groups based on anatomic predisposition. Tumor volumes across
all regions were combined and scaled for each patient; scores were
then analyzed by agglomerative hierarchical clustering. We
partitioned the resulting dendrogram and assessed possible
associations between the resulting groups and the following
variables by a series of Chi-square tests: diagnosis, number of
cafe´-au-lait macules, presence of skeletal abnormalities, presence
of gliomas, inheritance pattern, presence of cutaneous tumors, and
gender. We assessed the variable age using Kruskal-Wallis test.
All statistical calculations were performed with SAS software
(version 9.2, SAS Institute Inc, NC, USA) and the statistical
programming language R.[20] The distribution and cluster
analyses were designed post-hoc. The study was approved by the
institutional review boards at Massachusetts General Hospital
(Partners Human Research Committee); University of Hamburg,
Eppendorf, Germany (Ethics Committee of the Chamber of
Physicians, Hamburg); and the Department of Defense (Human
Research Protection Office). Written informed consent was
obtained from all participants.
Results
Study patients
Between January 2007 and November 2010, a total of
247 patients underwent WBMRI. The cohort included 141 NF1
patients (57%), 55 NF2 patients (22%), and 51 schwannomatosis
patients (21%). Baseline demographic and clinical characteristics
of the cohort are shown in Tables 1 and 2, respectively.
Whole-body tumor count and volume
We identified a total of 1286 nerve sheath tumors (528
plexiform and 758 circumscribed tumors) comprising 65,423 ml
in 145/247 patients (59%). Internal tumors were more common in
schwannomatosis patients (71%) than in NF2 patients (45%)
(p = 0.01); the prevalence in NF1 patients (60%) was not
significantly different than either schwannomatosis or NF2
patients (p.0.05). Plexiform tumors were found in all three
groups, more commonly in NF1 patients (40%) than in NF2 and
schwannomatosis patients (18% and 14%, respectively) (p = 0.01).
Among 76 patients who denied a history of internal nerve sheath
tumors at enrollment, 30 (39%) were found to have tumors on
WBMRI. This group included 22/52 NF1 patients (42%), 1/16
NF2 patients (6%), and 7/8 schwannomatosis patients (88%).
In patients with internal tumors on WBMRI, tumor count
ranged from 1 to 69; the distribution of tumor count per patient
showed an exponential decline (Figure 2A). In patients with at least
one tumor, the median number of tumors did not differ by
diagnosis (Table 3). In logistic regression analysis, the presence of
internal nerve sheath tumors was correlated with decreasing
number of cafe´-au-lait macules in NF1 patients (P = 0.003) and
with history of skeletal abnormalities in NF2 patients (P = 0.09)
(Figure 3). All other clinical factors had P-values .0.10, the level
of significance used for this exploratory correlative analysis.
In patients with internal tumors, whole-body tumor volume per
patient ranged from 1.2 ml to 9106.1 ml; the distribution of total
tumor volume showed a progressive decline in frequency as tumor
volume increased (Figure 2B). The median whole-body tumor
volume for all groups was 83.0 ml and differed among diagnosis
groups (p = 0.02, Table 3). Although 41% (528/1286) of lesions
were plexiform in appearance, these tumors contributed 78% of
the total tumor volume: the median tumor volume was 29.4 ml
per plexiform tumor and 6.7 ml per circumscribed tumor. In
multivariable analysis, increased tumor volume was correlated
with female gender (P= 0.05) and with presence of subcutaneous
neurofibromas (P= 0.03) in NF1 patients, with the absence of
cutaneous schwannomas in NF2 patients (P = 0.06), and with
increasing age in schwannomatosis patients (P = 0.10). All other
clinical factors had P-values .0.10.
Table 1. Demographic features of the 247 patients who underwent whole-body MRI.
Demographic features
Neurofibromatosis 1
N=141
Neurofibromatosis 2
N=55
Schwannomatosis
N=51 P-value
Mean age (years) 38.5 39.1 48.5 , 0.001
Mean age at diagnosis (years) 14.5 29.1 41.8 , 0.001
Mean age at diagnosis of first
internal tumor (years)
18.7 28.1 37.4 , 0.001
Sex (%)-male 46.8% 41.8% 51.0% .64
Mean height (cm) 167 167 170 .006
Mean weight (kg) 71 69 81 , 0.001
Highest degree
High school or less 45% 27% 27%
College or higher 55% 73% 73%
Inheritence .17
Familial 42 (29.8%) 14 (25.5%) 8 (15.7%)
Sporadic 98 (69.5%) 41 (74.5%) 41 (80.4%)
Unknown 1 (0.7%) 0 (0%) 2 (3.9%)
doi:10.1371/journal.pone.0035711.t001
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Distribution analysis of internal nerve sheath tumors
The median Gini coefficient was 0.84 (range, 0.26 to 1.0),
suggesting that tumor volume within patients was not evenly
distributed across body parts. The majority of patients (122/144,
85%) had high Gini coefficients ($0.67) indicating that tumor
volume was concentrated in a limited region. Seventeen patients
(12%) had moderate Gini coefficients (0.34–0.66), and just
5 patients (3%) had low Gini coefficients (#0.33) indicating even
distribution of tumor volume across body parts. The complete
collection of WBMRI with tumor volumes and Gini coefficients
can be viewed at www.wholebodymri.org.
Overall, the legs harbored the greatest volume of tumors (31%),
followed by the pelvis (22%), thorax (17%), abdomen (13%), arms
(11%) and head/neck (6%) (Figure 2C). When compared with the
relative volume of each body part, the distribution showed that the
head/neck and pelvis were over-represented while the legs were
under-represented (p,0.001, Figure 2D).
Clustering of our data set revealed distinct groups of patients
based on predominant tumor location. The most common pattern
was leg-predominant (54/145, 37%), followed by pelvis-predom-
inant (32/145, 22%), thorax-predominant (22/145, 15%), head/
neck-predominant (14/145, 10%), abdomen-predominant (13/
145, 9%), and arms-predominant (10/145, 7%) (Figure 4).
Clustering was associated with age (p= 0.06) and with
inheritance pattern (sporadic vs. familial) (P = 0.1). Patients were
then dichotomized according to median age at diagnosis
(#20 years vs. .20 years), median age at WBMRI (#40 years
vs. .40 years), and inheritance pattern for comparison of relative
tumor volume across body regions. There was no significant
difference between sporadic and familial patients or between
patients diagnosed before or after 20. However, patients
#40 years had a higher proportion of tumor volume in the pelvis
and legs compared those .40 (Figure 5). Clinical variables which
did not differ significantly among clusters included diagnosis,
numbers of cafe´-au-lait macules, skeletal abnormalities, gender,
number of cutaneous neurofibromas, and presence of gliomas
(p.0.1).
Table 2. Clinical features of the 247 patients who underwent whole-body MRI.
Neurofibromatosis 1
(n=141)
Neurofibromatosis 2
(n =55)
Schwannomatosis
(n =51)
Medical history
Plexiform neurofibroma 76/140 (54%) Vestibular schwannoma 54/55 (98%) Vestibular schwannoma 0/51 (0%)
Spinal neurofibroma 33/139 (24%) Spinal schwannoma 30/52 (58%) Spinal schwannoma 27/50 (54%)
Optic glioma 16/141 (11%) Internal schwannoma 19/52 (37%) Internal schwannoma 30/51 (59%)
Non-optic glioma 12/141 (8.5%) Meningioma 29/54 (54%) Meningioma 0/48 (0%)
GIST 3/137 (2%) Ependymoma 19/53 (36%) Ependymoma 0/44 (0%)
Pheochromocytoma 5/137 (4%) Hearing loss 52/54 (96%) Hearing loss 7/51 (14%)
$ 2 Lisch nodules 62/113 (55%) Tinnitus 39/55 (71%) Tinnitus 3/51 (6%)
ADHD 20/139 (14%) Epiretinal membrane or retinal
hamartoma
4/46 (9%) Epiretinal membrane or retinal
hamartoma
0/30 (0%)
Learning disability 43/138 (31%) Cataracts 13/46 (28%) Cataracts 5/30 (17%)
Seizures 7/141 (5%) Seizures 8/55 (15%) Seizures 1/51 (2%)
Skeletal complication 44/140 (31%) Skeletal complication 6/55 (11%) Skeletal complication 3/51 (6%)
Scoliosis 40 (28%) Scoliosis 6 (11%) Scoliosis 3 (6%)
Pseudarthrosis 1 (1%) Pseudoarthrosis 0 (0%) Pseudoarthrosis 0 (0%)
Sphenoid wing dysplasia 1 (1%) Sphenoid wing dysplasia 0 (0%) Sphenoid wing dysplasia 0 (0%)
Bone cysts 2 (1%) Bone cysts 0 (0%) Bone cysts 0 (0%)
Physical examination
$ 6 cafe-au-lait macules 111/140 (79%) $ 6 cafe-au-lait macules 3/55 (5%) $ 6 cafe-au-lait macules 0/51 (0%)
Skin fold freckling 125/141 (89%)
Cutaneous neurofibromas 119/141 (84%) Cutaneous schwannomas 21/55 (38%) Cutaneous schwannomas 9/51 (18%)
, 10 21 (15%) 1–5 16 (29%) 1–5 9 (18%)
10–100 46 (33%) 6–10 4 (7%) 6–10
101–500 33 (23%) .10 1 (2%) .10
. 500 19 (13%)
Subcutaneous neurofibromas 110/141 (78%) Subcutaneous schwannoma 15/55 (27%) Subcutaneous schwannomas 18/51 (35%)
, 10 51 (36%) 1–5 12 (22%) 1–5 13 (25%)
10–100 38 (27%) 6–10 3 (5%) 6–10 3 (6%)
101–500 17 (12%) .10 0 (0%) .10 2 (4%)
. 500 4 (3%)
doi:10.1371/journal.pone.0035711.t002
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Discussion
In this study, we used WBMRI to examine internal tumor
burden in three closely related tumor-suppressor syndromes. Our
findings corroborate that WBMRI can detect internal tumors in a
far higher percentage of patients than conventional, regional
imaging methods.[21] For example, the prevalence of plexiform or
spinal nerve sheath tumors on regional MRI or CT scan ranges
from 16%–39% in NF1 patients.[17,22–25] Using WBMRI, we
found that 60% of such patients have internal nerve sheath
tumors. As expected, patients without a known history of internal
tumor had high rates of lesions on WBMRI, indicating that
asymptomatic tumors are common in this population [25].
Because WBMRI can detect even relatively small or asymp-
tomatic tumors in all body regions, it provides a more
comprehensive picture of tumor burden in patients and, for the
first time, allows for analysis of tumor distribution across body
parts. We used novel approaches to describe this distribution,
including Gini coefficient to measure the regionality of tumor
burden and clustering analysis to sort patients into groups based
on tumor predilection. Our results show that internal nerve sheath
tumors, like dermal neurofibromas, are not randomly or evenly
distributed across body parts (see www.wholebodymri.org).
Instead, particular body regions appear to be preferentially
affected, while other body regions are relatively spared.
There are multiple processes that might explain why the pelvis
and head/neck are particularly affected by internal tumors or why
younger patients have a greater proportion of internal tumor
volume in the pelvis and legs. Genetic mosaicism is well
documented in neurofibromatosis and may be diagnosed when
patients display disease features that are restricted to portions of
the body (e.g., segmental findings).[26,27] Alternatively, there may
be tissue-specific biological factors in the affected regions that are
permissive for tumor formation. It is increasingly clear that
neurofibroma formation requires a microenvironment containing
bone marrow-derived cells that are heterozygous at Nf1.[28] These
biological factors could be important during development (e.g., for
congenital lesions like plexiform neurofibromas) or post-natally
(e.g., for non-congenital lesions like vestibular schwannomas).
Genetically engineered mouse (GEM) models of NF1 and NF2
develop nerve sheath tumors in restricted locations that differ from
humans.[29–31] Subsequent investigations of molecular biomark-
ers in both GEM and human tissue may help identify biological
factors involved in these unique disease manifestations.
Overall, tumor burden and patterns of regionality were similar
for the three tumor-suppressor syndromes. We observed a high
prevalence of nerve sheath tumors in schwannomatosis patients
(71%), NF1 patients (60%), and NF2 patients (42%). There was no
difference in the median number of tumors but there was greater
median tumor volume in NF1 patients than in NF2 or
schwannomatosis patients. This difference was due to the
increased prevalence of larger plexiform tumors in this population.
The overall similarity in tumor burden among these conditions is
striking given the diverse functions of the NF1, NF2, and
SMARCB1 tumor-suppressor genes. Inactivation of NF1 leads to
upregulation of RAS signaling [32]; inactivation of NF2 leads to
dysregulation of cell surface receptors and intercellular signaling,
and to disinhibition of the E3 ubiquitin ligase
CRL4(DCAF1)[33,34]; and inactivation of SMARCB1 leads to
dysregulation of the SWI-SNF chromatin remodeling complex
[35]. Current laboratory models do not explain the precise
interaction between these pathways, but can be used to explore
whether these separate pathways converge upon a final common
pathway in Schwann cells.
Having an accurate phenotype of patients not only provides a
basis for future research investigations, but has important
Figure 2. Number, volume, and anatomic distribution of internal nerve sheath tumors. Waterfall plot of tumor count (panel A) and tumor
volume (Panel B) in 145 patients with at least one internal tumor. Anatomic distribution of relative tumor volume given as a percentage of whole-
body volume (Panel C) and corrected for volume per body part (Panel D).
doi:10.1371/journal.pone.0035711.g002
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implications for clinical management of NF patients. Our data
identifies clinical risk factors for internal nerve sheath tumors in
the neurofibromatoses; this information builds upon established
genetic factors that influence tumor burden, such as NF1 gene
microdeletions (increased tumor burden) [36] and mosaicism for
the NF2 gene (decreased tumor burden).[27] In NF1 patients,
decreasing number of cafe-au-lait macules correlated with the
presence, but not volume, of internal neurofibromas (Figure 3).
This finding, which was reported recently,[14] was not explained
by increasing age since this variable was included in the
multivariate model. An inverse relationship between the presence
of neurofibromas and cafe´-au-lait macules – the two cardinal
features of NF1 – has been reported in rare variants of NF1.
Patients with spinal neurofibromatosis have multiple spinal
neurofibromas without cafe´-au-lait macules whereas patients with
a 3-bp inframe deletion in exon 17 of the NF1 gene have cafe´-au-
lait macules without neurofibromas.[37] Our data suggests that
this inverse relationship may apply to a broader subset of patients
than previously recognized. Further research should examine
differential effects of germline NF1 mutations on melanocytes and
Schwann cells since both are derived from neural crest cells.
Figure 3. Odds ratios for the presence of internal nerve sheath tumors. Odds ratio for the presence of internal nerve sheath tumors in NF1,
NF2, and schwannomatosis patients, according to clinical and demographic characteristics. Odds ratios and 95% confidence intervals were calculated
with the use of logistic regression analsysis. Squares indicate odds ratios and horizontal lines indicate 95% confidence intervals. P values are for the
odds ratios.
doi:10.1371/journal.pone.0035711.g003
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Increasing numbers of subcutaneous tumors correlated with
increasing neurofibroma volume in NF1 patients, corroborating
previous reports [38] and presumably reflecting their shared
biologic underpinnings with internal tumors. We also found that
women with NF1 have greater tumor burden, on average, than
men. Although the biological basis for this finding is not known,
some studies have suggested that sex hormones may stimulate
tumor growth. For example, tumor number and size increase in
women during pregnancy,[17,39] and in women using contra-
ception with high doses of synthetic progesterone.[40] In addition,
laboratory studies have implicated progesterone in neurofibroma
progression.[41] Additional studies on the effect of sex hormones
on tumor formation and growth are warranted to clarify this
finding.
Our data identify scoliosis and decreasing numbers of cutaneous
schwannomas as risk factors for internal schwannomas in NF2.
While the presence of internal schwannomas correlated with
scoliosis, it did not correlate with established markers of disease
Table 3. Whole-body tumor number and volume in patients with at least 1 internal tumor.
Characteristic
NF1
N=84
NF2
N=25
Schwannomatosis
N=36 p-value
All tumors Median number of tumor per patient 4.5 2.0 4.0 0.21
Median tumor volume per patient – ml 107.9 69.5 39.4 0.02
Circumscribed tumors Median number of tumor per patient 3.0 2.0 5.0 0.30
Median tumor volume per patient – ml 29.9 38.8 31.3 0.53
Plexiform tumors Median number of tumor per patient 3.0 3.0 3.0 0.70
Median tumor volume per patient – ml 205.2 124.6 107.5 0.76
doi:10.1371/journal.pone.0035711.t003
Figure 4. Results of unsupervised hierarchical clustering of patients based on relative tumor volume across body regions. (This
figure is an interactive display. It is currently available for at www.wholebodymri.org). Unsupervised hierarchical clustering of relative tumor volume
across body region (head/neck, trunk, extremities) for 145 subjects with internal nerve sheath tumors. Total tumor volumes were combined and
scaled for each patient. Regions with higher tumor burden are shown in yellow. Individual patients are represented as columns and the maximum
intensity projection (MIP) of the whole-body MRI scan is shown to the right of the clustering figure. For each patient, the Gini coefficient is shown in
the lower left and the whole-body tumor volume in the lower middle.
doi:10.1371/journal.pone.0035711.g004
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severity such as spinal tumors or meningiomas.[15,16] For this
reason, we suspect that scoliosis may result from spinal tumors
rather than being a predisposing factor. Unexpectedly, whole-
body tumor volume in NF2 patients was inversely correlated with
the number of cutaneous schwannomas.[15] If this finding is
confirmed, it further highlights the importance of different
microenviroments in tumor formation. In schwannomatosis
patients, no risk factors were identified for the presence of internal
schwannomas although increasing age correlated with whole-body
tumor volume. This finding may explain, in part, the late age at
onset of symptoms compared to NF1 and NF2 [5].
The limitations of our study include the use of a sample of
convenience at two large referral centers and the lack of children
in the study population. For this reason, our study population does
not represent all patients with neurofibromatosis or schwannoma-
tosis. Additionally, coverage of the legs and arms by WBMRI may
be incomplete in individuals who are tall or heavy. Our study did
not include serial WBMRI scans of individual patients and
therefore cannot determine the rate by which tumor count or
volume changed with time. Future longitudinal studies of WBMRI
in NF patients should quantify changes in tumor burden over time
to better understand tumor progression.
In conclusion, in this large prospective international study, we
found high rates of internal nerve sheath tumors in neurofibro-
matosis patients and showed that tumors were non-randomly
distributed across body parts. These results provide valuable
information about risk factors for internal nerve sheath tumors and
raise new biological questions for future research. The addition of
WBMRI to careful phenotyping represents a powerful approach to
studying hereditary tumor predisposition syndromes and other
complex genetic syndromes in humans.
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